It is made available under a CC-BY 4.0 International license .

1	Utilizing Electronic Health Records (EHR) and Tumor Panel
2	Sequencing to Demystify Prognosis of Cancer of Unknown
3	Primary (CUP) patients
4 5 6	Intae Moon ^{1,5,*} , Jaclyn LoPiccolo ² , Sylvan C. Baca ^{2, 3} , Lynette M. Sholl ⁴ , Kenneth L. Kehl ⁵ , Michael J. Hassett ⁵ , David Liu ^{2, 6} , Deborah Schrag ⁷ , and Alexander Gusev ^{5, 6, 8, *}
7	¹ Department of Electrical Engineering and Computer Science, Massachusetts
8	Institute of Technology, Cambridge, MA, USA
9	² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
10	³ Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston,
11	Massachusetts.
12	⁴ Department of Pathology, Brigham and Women's Hospital, Harvard Medical
13	School, Boston, MA, USA
14	⁵ Division of Population Sciences, Dana-Farber Cancer Institute and Harvard
15	Medical School, Boston, MA, USA
16	⁶ The Broad Institute of MIT & Harvard, Cambridge, MA, USA
17	⁷ Memorial Sloan Kettering Cancer Center, New York, NY, USA
18	⁸ Division of Genetics, Brigham and Women's Hospital and Harvard Medical School,
19	Boston, MA, USA
20	* Corresponding author, alexander_gusev@dfci.harvard.edu

21

Abstract

When a standardized diagnostic test fails to locate the primary site of a metastatic cancer, 22 it is diagnosed as a cancer of unknown primary (CUP). CUPs account for 3-5% of all cancers 23 but do not have established targeted therapies, leading to typically dismal outcomes. Here, we 24 develop OncoNPC, a machine learning classifier of CUP, trained on targeted next generation 25 sequencing data from 34,567 tumors across 22 primary cancer types collected as part of routine 26 clinical care at three institutions under AACR Project GENIE initiative [1]. OncoNPC achieved 27 a weighted F1 score of 0.94 for high confidence predictions on known cancer types (65% of 28 held-out samples). To evaluate its clinical utility, we applied OncoNPC to 971 CUP tumor 29 samples from patients treated at the Dana-Farber Cancer Institute (DFCI). OncoNPC CUP 30

It is made available under a CC-BY 4.0 International license .

subtypes exhibited significantly different survival outcomes, and identified potentially actionable

molecular alterations in 23% of tumors. Importantly, patients with CUP, who received first

palliative intent treatments concordant with their OncoNPC predicted sites, showed significantly

better outcomes (Hazard Ratio 0.348, 95% C.I. 0.210 - 0.570, p-value 2.32×10^{-5}) after accounting

- for potential measured confounders. As validation, we showed that OncoNPC CUP subtypes
- exhibited significantly higher polygenic germline risk for the predicted cancer type. OncoNPC
- thus provides evidence of distinct CUP subtypes and offers the potential for clinical decision
- support for managing patients with CUP.

³⁹ Introduction

When a standardized diagnostic work-up, including radiology and pathology review, fails to locate 40 the primary site of a metastatic cancer, it is diagnosed as a cancer of unknown primary (CUP). CUP 41 represents about 3-5% of all cancers worldwide [2] and is characterized by aggressive progression 42 and poor prognosis (survival of 6 to 16 months [3]). The hidden nature of the primary cancer 43 types for a CUP limits treatment options since clinical responses to some treatments are known to 44 vary based on patients' tumor types (e.g., identical BRAF V600 mutations targetable in melanoma 45 but no colorectal cancer[4]). Emerging cancer treatments targeting actionable molecular alterations 46 are typically developed for specific cancer types: HER2 in breast cancer and EGFR mutation or 47 ALK/ROS1 rearrangement in Non-small cell lung cancer (NSCLC) [5], and are thus inaccessible to 48 CUP patients. Accurately identifying the latent primary site for CUPs and demonstrating clinical 49 benefit from site-specific therapies may thus open many existing treatment options for patients with 50 CUP. 51

Pathology review plays a key role in determining primary cancer types of malignant tumors based 52 on immunohistochemistry (IHC) results as well as tumor morphology and clinical findings; however, 53 pathological diagnosis can be challenging for highly metastatic or poorly differentiated tumors. For 54 known cancer types, prior studies showed that an IHC-based diagnostic work-up correctly identified 55 77 - 86% of primary tumors, which further decreased to 60 - 71% for metastatic tumors [6]. For 56 patients with CUP, IHC results suggestive of a single primary diagnosis account for only 25% of 57 tumors [3]. The subjective nature of pathological interpretation and guidelines, as well as the 58 variability in IHC staining techniques across institutions thus makes it challenging to establish 59 consistent protocols for CUP diagnosis [7]. 60

Molecular tumor profiling has been proposed as an alternative for CUP primary classification 61 due to its quantitative nature and high accuracy on tumors with known cancer types [8–12]. Such 62 tools rely on microarray DNA methylation [8], whole genome sequencing (WGS) [9, 12], or RNA-63 seq data [11] to train machine learning classifiers using reference data from known-primary tumors. 64 However, molecular sequencing remains prohibitive and not integrated into the existing standard 65 of care, limiting the translational potential of such methods. Recently, key work by Penson et 66 al. [10] demonstrated that accurate primary cancer type classifications could be made from next 67 generation sequencing (NGS) of targeted panels, now routinely collected at many cancer centers and 68 applicable to hundreds of thousands of tumors [1]. However, its clinical utility in diagnosing and 69

It is made available under a CC-BY 4.0 International license .

⁷⁰ aiding treatment for patients with CUP was not systematically investigated.

Several recent studies have investigated the potential clinical benefit of molecular CUP clas-71 sification, in non-randomized prospective studies [13–15] as well as the randomized clinical trials 72 [16]. These trials have often struggled to recruit sufficient numbers of representative patients and 73 explore the full range of available therapies. A recent randomized phase II trial [16] did not find 74 significant improvement in 1-year survival for the treatment group receiving site-specific therapy 75 guided by molecular profiling. However, this study was limited by a small number of patients (n =76 101) recruited over 7 years, with few common solid tumor types and well-established therapies [17]. 77 Assessing the clinical benefits of molecular CUP classification thus poses both an opportunity for 78 precision medicine and a major challenge for conventional randomized studies. 79 In contrast to prospective trials, retrospective Electronic Health Records (EHR) data can cap-80 ture a larger and more heterogeneous patient population, despite potential biases due to informative 81 missingness and unobserved heterogeneity. Coupling EHR data with tumor sequencing can offer 82 insights into the molecular mechanisms of CUPs and their relationship to clinical outcomes. As 83 panel sequencing is often part of the standard of care, such insights also have the potential to assist 84 diagnostic efforts and clinical management within existing molecular workflows. Here, we utilized 85 multi-center, Next Generation Sequencing (NGS) targeted panel sequencing data from 36,445 tumor 86 samples with known primary cancers to train and evaluate a machine learning classifier predicting a 87 primary cancer type of a given tumor sample. We applied this classifier, named OncoNPC (**Onco**logy 88 NGS-based Primary cancer type Classifier), to 971 patients with CUP with clinical follow up at the 89 Dana-Farber Cancer Institute (DFCI). Using the OncoNPC cancer type predictions, we identified 90 CUP subtypes that shared specific characteristics with their corresponding predicted primaries in-91 cluding: significant differences in clinical outcomes, elevated germline risk, and prognostic somatic 92 alterations. 23% of OncoNPC classified CUP tumors had actionable somatic variants enabled by 93 their corresponding OncoNPC cancer type predictions. Finally, using EHR-based treatment and 94 survival data, we showed that site-specific treatments concordant with the OncoNPC cancer type 95 predictions led to longer survival than those discordant with the cancer type predictions. Our find-96 ings suggest that many CUPs can be classified into meaningful subtypes with the potential to aid 97 clinical decision making. 98

" Results

¹⁰⁰ OncoNPC accurately classifies 22 known cancer types

We developed *OncoNPC* (Oncology NGS-based Primary cancer type Classifier), a molecular cancer type classifier trained on multicenter targeted panel sequencing data (Fig. 1). OncoNPC utilized all somatic alterations including mutations (single nucleotide variants and indels), mutational signatures, copy number alterations, as well as patient age at sequencing and sex to jointly predict cancer type using a XGBoost algorithm (see Methods). Importantly, no other aspects of tumor morphology, pathology, or patient demographics were used so as not to bias the classifier towards known cancers. OncoNPC was trained and validated on the processed data consisting of 29,176 primary

It is made available under a CC-BY 4.0 International license .

and metastasis tumor samples from 22 known cancer types collected at the DFCI, MSK, and VICC 108 (see Table 1 for details). Across all 22 cancer types, OncoNPC achieved a weighted F1 score of 0.784 109 on the held-out test tumor samples consisting of 7,289 tumor samples (weighted precision and recall 110 : 0.789 and 0.791, respectively). Across 10 cancer groups (grouped by sites and treatment options 111 (Table 1), OncoNPC achieved an overall weighted F1 score of 0.824 (weighted precision and recall : 112 0.829 and 0.826, respectively). Despite the evident class imbalance across cancer types, OncoNPC 113 showed well-balanced precision across the cancer types (Fig. 2a) and cancer groups (Fig. 2b). 114 Thresholding on prediction confidence $(p_{max}, \text{ the maximum posterior probability across all labels})$ 115 further increased the performance: weighted F1 score of 0.830 with 91.6 % remaining samples at 116 $p_{max} \ge 0.5$ and 0.942 with 65.2 % remaining samples at $p_{max} \ge 0.9$ (Fig. 2c, 2d). While rarer cancer 117 types had generally lower overall performance, increasing the p_{max} threshold reduced this difference 118 between common/rare cancer types (Fig. 2c, 2d). At $p_{max} \ge 0$, common cancer types in the upper 119 quartile in terms of the number of tumor samples (NSCLC, BRCA, COADREAD, DIFG, PRAD, 120 and PAAD) had a mean F1 of 0.84 while rare cancer types in the lower quartile (WDTC, MNGT, 121 GINET, PANET, AML, and NHL) had a mean F1 of 0.58, whereas at $p_{max} \ge 0.9$ common and rare 122 cancer had a mean F1 of 0.95 and 0.86, respectively. This demonstrates that the OncoNPC was 123 still able to do high-quality predictions for a subset of tumor samples in rare cancer types, for which 124 training data was limited. 125

OncoNPC achieved robust performance against potential dataset shifts due to the factors includ-126 ing cancer center, biopsy site type, sequence panel version, and patient ethnicity (Fig. 2e). OncoNPC 127 showed comparable performance for tumor samples from DFCI (AUC-PR, area under the precision 128 recall curve = 0.89, n = 3,690) and those from MSK (AUC-PR = 0.85, n = 3,331). OncoNPC 129 performance for those from VICC was slightly lower (AUC-PR = 0.76, n = 268). OncoNPC showed 130 comparable performance for primary tumor samples (AUC-PR = 0.87, n = 4,525) and metastatic 131 tumor samples (AUC-PR = 0.87, n = 2,605), demonstrating its capability to predict the primary 132 cancer site of metastatic cancers without loss of performance. To assess the OncoNPC performance 133 over time, we investigated its performance across sequence panel versions utilized at DFCI, as the 134 panel version is a proxy for sequence dates of tumor samples (see Table 1). The OncoNPC perfor-135 mance on tumor samples from earlier versions of DFCI sequence panels (OncoPanel v1 : AUC-PR 136 = 0.82, n = 414 and OncoPnael v2 : AUC-PR = 0.89, n = 1,050) was slightly lower than the per-137 formance on the tumor samples from the most recent panel (OncoPanel v3 : AUC-PR = 0.91, n = 138 2,226) which also contained the largest number of genes. As all tumor samples have been collected 139 from OncoPanel v3 since October 2016, we expect our model to make high-quality predictions in 140 a prospective setting. Finally, OncoNPC demonstrated consistent performance across patient eth-141 nicity, an important consideration to avoid introducing algorithmic disparities. See Supplementary 142 Fig. S1a for more detailed center-specific OncoNPC performance. 143

¹⁴⁴ Applying OncoNPC to CUP tumor samples

We applied OncoNPC to classify 971 CUP tumors from patients who were admitted to DFCI and sequenced as part of routine clinical care. Compared to the held-out cohort of Cancer with Known

It is made available under a CC-BY 4.0 International license .

Primary (CKP; n = 7,289), OncoNPC classifications for CUPs had prediction probabilities lower 147 than those of the DFCI held-out cohort of Cancer with Known Primary (CKP; n = 3.690), but 148 comparable to those of the DFCI held-out cohort of CKPs including other cancer types (n = 8,025), 149 indicating that CUPs may contain other hard-to-classify cancer types: mean prediction probabil-150 ity 0.764 (95% C.I. 0.750 - 778) for CUPs versus 0.881 (95% C.I. 0.875 - 0.887) for the held-out 151 CKPs at DFCI and 0.769 (95% C.I. 0.764 - 0.774) for all held-out CKPs at DFCI (Fig. S1 and 152 Supplementary Fig. S1b). However, more than half of the CUP tumors (518/971) could still be 153 classified with high confidence (i.e., prediction probability > 0.8), and multiple classified types had 154 distributions of posterior probabilities comparable to their corresponding CKPs: Non-small Cell 155 Lung Cancer (NSCLC), Invasive Breast Carcinoma (BRCA), Pancreatic Adenocarcinoma (PAAD), 156 Prostate Adenocarcinoma (PRAD), and Gastrointestinal Neuroendocrine Tumors (GINET). Inter-157 estingly, CUPs with predicted GINET were highly confident, despite their small number of tumor 158 samples in the training cohort (n = 359; 0.99% of the training cohort), suggesting some rarer cancer 159 types may nevertheless be confidently identifiable. As shown in Fig. 3b, the most common CUP can-160 cer types were Non-small Cell Lung Cancer (NSCLC), Pancreatic Adenocarcinoma (PAAD), Invasive 161 Breast Carcinoma (BRCA), Esophagogastric Adenocarcinoma (EGC), and Colorectal Adenocarci-162 noma (COADREAD); of which NSCLC, BRCA, and COADREAD were also the most common 163 CKP types. These rates are broadly consistent with prior findings that the most frequently revealed 164 underlying primary cancers for CUPs by autopsy include lung, large bowel, and pancreas cancers 165 [18]. Finally, comparable rates were observed upon applying OncoNPC to 581 CUP tumors at MSK 166 (Supplementary Fig. S4) 167

¹⁶⁸ Explaining OncoNPC cancer type predictions

OncoNPC learns complex non-linear relationships between input somatic variants and clinical fea-169 tures and provides interpretable primary cancer type predictions, where impact of each input feature 170 on a prediction is quantified as a SHAP value [19]. We investigated the most impactful features in 171 predicting each cancer type across the CKP and CUP cohorts to evaluate face validity of OncoNPC 172 (see Fig. 3d for the top 3 most frequent cancer types in the cohort: NSCLC, BRCA, and PAAD, and 173 Supplementary Fig. S2 and S3 for other cancer types). For NSCLC, the most important features 174 were EGFR mutation and SBS4, a tobacco smoking-associated mutation signature [20], for CKP 175 tumor samples and CUP with NSCLC predicted tumor samples, respectively; both consistent with 176 the known etiology of lung cancer. Somatic mutation in the EGFR gene is frequently observed in 177 NSCLC tumors and the gene itself is a well-known therapeutic target for patients with NSCLC [21, 178 22]. Carcinogens in tobacco smoke have been known to cause lung cancer [23]. For BRCA, the 179 most important feature for both CKP and CUP was sex, as expected, followed by CNA events in 180 GATA3 and CCND1 genes, known drivers and prognostic indicators in breast cancer [24, 25]. For 181 PAAD, KRAS mutation was significantly more common than the population averages and by far 182 the most important somatic feature. Mutations in the KRAS gene occur frequently among patients 183 with colorectal cancer and are known to have prognostic significance [26, 27]. 184

OncoNPC provides intuitive illustrations of an explanation for individual-level predictions (Fig.

It is made available under a CC-BY 4.0 International license .

3e). As an example, we show the explained classification for a tumor sample biopsied from the 186 liver of the 76 year-old male patient and subsequently diagnosed with CUP. From the chart review, 187 we found that the patient reported a 60-pack year smoking history, as well as having lived near a 188 tar and chemical factory as a child. Despite the CUP diagnosis, OncoNPC confidently classified 189 the primary site as NSCLC with posterior probability of 0.98. SBS4, a tobacco smoking-associated 190 mutation signature, was significantly enriched in the patient's tumor sample, which has, by far, 191 the most impact on the prediction; followed by SBS24 mutation signature associated with known 192 exposures to aflatoxin [20]; and KRAS mutation. Note that inhalation of aflatoxin has been linked 193 to cause primary lung cancer [28–30], and KRAS mutation is one of the most common drivers 194 of NSCLC [31, 32]. The feature interpretation analysis demonstrated that OncoNPC was able to 195 capture biologically consistent, cancer-type specific signals from interpretable somatic mutation and 196 clinical features at an individual tumor level as well as a cohort level. 197

¹⁹⁸ Germline PRS-based validation on CUP tumor samples

We hypothesized that, if OncoNPC was accurately identifying latent primary cancers, the classified 199 CUP cancer types would exhibit increased germline risk for the corresponding cancers. To that end, 200 we imputed common germline variation for each CUP patient and quantified their polygenic risk 201 scores (PRS) across 8 common cancers using external cancer GWAS data (see Methods). PRSs are 202 a continuous estimate of the underlying germline liability for a given cancer and orthogonal from the 203 somatic data used to train OncoNPC. As hypothesized, patients with CUP had a significantly higher 204 mean germline PRS for the OncoNPC predicted cancers (Fig. 3c and see Supplementary Fig. S6 205 for cancer type-specific analysis) compared to other cancer types. The magnitude of the difference 206 (i.e., $\hat{\Delta}_{PRS}$) increased for more confident OncoNPC predictions ($\hat{\Delta}_{PRS} = 0.142, 95\%$ C.I. 0.0494 – 207 0.235, Wald test p-value: 2.66×10^{-3} and $\hat{\Delta}_{PRS} = 0.204, 95\%$ C.I. 0.0655 - 0.344, Wald test p-value: 208 3.98×10^{-3} at $p_{\rm max}$ threshold = 0.0 and $p_{\rm max}$ threshold = 0.9, respectively). As a negative control, 209 the same analysis conducted with randomly shuffled OncoNPC labels showed no enrichment. As a 210 positive control, the same analysis conducted on CKPs, with available imputed PRS (n = 11,332), 211 also demonstrated a highly significant germline enrichment, as expected. Notably, the enrichment for 212 CUPs was in between that of CKPs and random tumors, suggesting that while OncoNPC classified 213 CUPs are genetically correlated with CKPs, they still exhibit additional heterogeneity. 214

²¹⁵ OncoNPC-based risk stratification among patients with CUP

To demonstrate clinical utility of OncoNPC, we examined if OncoNPC cancer type predictions can 216 stratify risk among patients with CUP. Using overall survival, we identified subtypes which had 217 significant prognostic differences in median survival based on the OncoNPC classifications (Figure 218 4a, Chi-squared test, p-value: 4.90×10^{-14}). Overall, the poorest prognosis was observed in patients 219 with CUP predicted to be Esophagogastric Adenocarcinoma (EGC) and Pancreatic Adenocarci-220 noma (PAAD): median survival 8.44 months for the combined cohort (95% C.I. 5.39 - 10.5, n =221 107). The most favorable prognosis was observed in patients with CUP predicted to be Head and 222 Neck Squamous Cell Carcinoma (HNSCC), Gastrointestinal Neuroendocrine Tumors (GINET), and 223

It is made available under a CC-BY 4.0 International license .

Pancreatic Neuroendocrine Tumors (PANET): median survival 48.2 months for HNSCC (95% C.I. 19.6 - not estimable, n = 41) and not estimable median survival (i.e. the estimated survival curve never reached the median) for the combined GINET and PANET cohort (n = 57), respectively. Our identified favorable subtypes are consistent with established favorable CUP subtypes such as poorly or well differentiated neuroendocrine carcinomas of unknown primary and squamous cell carcinoma of non-supraclavicular cervical lymph nodes [33]. OncoNPC subtypes can thus be leveraged to meaningfully stratify patients by expected median survival.

²³¹ CUP-CKP metastatic survival comparison

We investigated if cancer-specific prognosis is shared between CUP predicted cancer and their cor-232 responding CKP metastatic cancers. Utilizing overall survival data linked to the National Death 233 Index and in-house follow-up data (see Methods), we found that median survival times of CUP-234 metastatic CKP pairs were significantly correlated across the cancer types (Spearman's ρ : 0.964, 235 p-value: 4.54×10^{-4} ; Fig. 4b). This significant relationship provides evidence that genetics-based 236 OncoNPC predictions capture prognostic signals specific to each predicted cancer type. While corre-237 lated, median survival times were significantly lower for patients with CUP compared to those with 238 metastatic CKP: CUP median survival 14.0 months (95% C.I. 11.9 - 15.8, n = 685) vs. metastatic 239 CKP median survival 23.1 months (95% C.I. 21.8 - 24.2, n = 7,797). This is expected as CUPs 240 are an advanced metastatic cancer with limited treatment options [33]. The absolute difference in 241 median survival was significant across all predicted CUP - metastatic CKP pairs with the exception 242 of Pancreatic Adenocarcinoma (CUP PAAD median survival 8.61 months 95% C.I. 5.09 - 10.8 vs. 243 metastatic CKP PAAD median survival 6.73 months 95% C.I. 5.98 - 8.02), known to be a particularly 244 deadly cancer type. 245

246 Shared prognostic somatic variants in CUP-metastatic CKP pairs

We aimed to identify prognostic somatic variants shared between OncoNPC CUP subtypes and their 247 corresponding metastatic CKP cancers. Three out of 14 tested CUP-metastatic CKP pairs (NSCLC, 248 PAAD, and COADREAD) exhibited shared prognostic somatic variants significantly associated with 249 overall survival with nominal p-value cut-off at 0.05 (Fig. 4c and 4d). In patients with known 250 or classified NSCLC, three somatic mutations were associated with poor survival in both groups: 251 SMARCA4 (CUP: H.R. 1.86, 95% C.I. 1.19 - 2.89, p-value 6.23×10^{-3} , CKP mets: H.R. 1.73, 252 95% C.I. 1.44 - 2.09, p-value 9.30 × 10⁻⁹), STK11 (CUP: H.R. 1.76, 95% C.I. 1.14 - 2.71, p-value 253 1.05×10^{-2} , CKP mets: H.R. 1.43, 95% C.I. 1.22 - 1.68, p-value 1.00×10^{-5}), and KEAP1 (CUP: 254 H.R. 1.83, 95% C.I. 1.18 - 2.85, p-value 6.82×10^{-3} , CKP mets: H.R. 1.40, 95% C.I. 1.18 - 1.66, 255 p-value 1.27×10^{-4}). These associations of somatic mutations in SMARCA4, STK11, and KEAP1 256 genes with overall survival are well established for NSCLC [34–36]. Interestingly, a CNA event in 257 NKX2-1 was associated with improved survival in the patients from the NSCLC pair (CUP: H.R. 258 0.542, 95% C.I. 0.326 - 0.901, p-value 1.83×10^{-2} , CKP mets: H.R. 0.770, 95% C.I. 0.662 - 0.894, 259 p-value 6.28×10^{-4}), consistent with prior meta-analyses [37]. In patients with known or classified 260 COADREAD tumors, SBS10b mutation signature, linked to polymerase epsilon exonuclease domain 26

It is made available under a CC-BY 4.0 International license .

mutations [20], was associated with longer overall survival (CUP: H.R. 0.371, 95% C.I. 0.148 - 0.928, 262 p-value 3.41×10^{-2} , CKP mets: H.R. 0.495, 95% C.I. 0.255 - 0.958, p-value 3.68×10^{-2}). Finally, in 263 patients with known or classified PAAD tumors, the SBS29 mutation signature (commonly found in 264 tumor samples from individuals with a tobacco chewing habit [20]) was associated with poor survival 265 in CUPs but nominally protective in metastatic CKPs (CUP: H.R. 2.66, 95% C.I. 1.02 - 6.93, p-value 266 4.46×10^{-2} , CKP mets: H.R. 0.657, 95% C.I. 0.438 - 0.986, p-value 4.28×10^{-2}). Although these 267 somatic associations remain to be validated in independent cohorts, by categorizing patients with 268 CUP based on their OncoNPC predictions, we were able to identify prognostic somatic variants, consistent with recent research findings. 270

Identifying actionable somatic variants in CUP tumors based on OncoNPCpredictions

We investigated if OncoNPC classifications could identify genetically driven, site-specific treatment 273 options that are typically available for cancers with known primaries. We utilized OncoKB [38] as 274 a knowledge base and considered three different categories of actionable somatic variants: onco-275 genic mutation, amplification, and fusion (see Methods). OncoNPC cancer type predictions enabled 276 identification of actionable somatic variants across CUP tumor samples (total 22.8% of the eligible 277 CUP tumor samples; see Fig. 5a and Fig. 5b). The majority of actionable somatic variants for 278 patients with CUP were oncogenic mutations (183 counts; 87.1%), followed by amplifications (22 279 counts; 9.52%) and fusions (7 counts; 3.33%) as shown in Fig. 5a. The four most frequent oncogenic 280 mutations were in PIK3CA, KRAS, ALK, and ERBB2 genes, occurring in CUP tumor samples 281 classified as BRCA (PIK3CA and ERBB2 genes) and NSCLC (KRAS, ALK, and ERBB2 genes). 282 Overall, among the eligible CUPs whose prediction confidences are greater than 0.5 (N = 794; see 283 Supplementary Fig. S5 for more details on the exclusion criteria), OncoNPC predictions identified 284 actionable somatic variants for 11.5% of the CUP tumor samples for Level 1 therapeutic level (FDA-285 approved drugs), 3.63% for Level 2 (Standard care), 6.64% for Level 3 (Clinical evidence), and 1.00% 286 for Level 4 (Biological evidence), summing up to the total 22.8% of the eligible CUP tumor samples 287 (Fig. 5b). 288

²⁸⁹ Survival benefit of treatment concordance with OncoNPC predictions

We performed retrospective survival analysis to investigate whether patients with CUP achieved 290 clinical benefit when treated in concordance with their OncoNPC classifications. We restricted to 291 a cohort of 158 patients with CUP, received first treatment at DFCI with a palliative intent (see 292 the exclusion criteria in Supplementary Fig. S5). Each case was then manually chart reviewed 293 by a certified oncologist to determine whether the treatment administered was concordant with the 294 OncoNPC prediction per National Comprehensive Cancer Network (NCCN) guidelines or standard of 295 care (see Methods, Fig. 5c, and Fig. 5d). Strikingly, patients with CUP who received first palliative 296 treatments concordant with their OncoNPC predicted cancer types exhibited significantly better 297 survival than those who received discordant treatments as shown in Fig. 5e and 5f (multivariable Cox 298 regression: H.R. 0.348, 95% C.I. 0.210 - 0.570, p-value 2.32×10^{-5} , Proportional Hazard assumption

It is made available under a CC-BY 4.0 International license .

test [39]: Chi-squared test with 17 degrees of freedom p-value 0.156, IPTW Kaplan-Meier estimator: weighted log-rank test p-value 4.25×10^{-10}). Finally, after stratifying by OncoNPC predicted cancers and repeating the IPTW Kaplan-Meier analysis, we found that the treatment concordant group had improved survival across cancer cohorts (breast, GI, and others), with the exception of the lung cancer cohort (Supplementary Fig. S7).

We note that as this was not a randomized analysis, a potential concern may be systematic 305 differences between the concordant and discordant groups leading to a significant prognostic but 306 not predictive difference [40]. For example, treatment discordant patients may have systematically 307 more advanced/de-differentiated tumors and thus exhibit poorer survival regardless of their treat-308 ment regimen. (see Table 2 for comparison of the two groups across the measured covariates). To 309 minimize biases from potential confounders and move towards a predictive estimate of treatment 310 concordance on patient survival, we adopted two estimation strategies: multivariable Cox regression 311 [41] (i.e., covariate adjustment) and Inverse Probability of Treatment Weighted (IPTW) Kaplan-312 Meier estimator [42] (see Methods), which have recently been employed to emulate estimates from 313 randomized trials [43, 44]. In both multivariable Cox regression and IPTW Kaplan-Meier estimator 314 strategies, patients treated like their OncoNPC predicted cancer types (i.e. those in the concor-315 dant treatment group) consistently showed significantly better survival compared to those in the 316 discordant treatment group. The multivariable Cox regression (Fig. 5e) additionally identified sig-317 nificant hazardous effects of age, gastrointestinal (GI) cancer types predicted by OncoNPC, and 318 bone metastasis (H.R. 1.27, 95% C.I. 1.02 – 1.58, p-value 3.10×10^{-2} , H.R. 4.20, 95% C.I. 2.06 – 319 8.55, p-value 7.78×10^{-5} , and H.R. 3.73, 95% C.I. 1.84 – 7.59, p-value 2.71×10^{-4} , respectively), and 320 significantly protective effects of tumor mutational burden (TMB), as well as adenocarcinoma and 321 neuroendocrine tumor group determined by the histopathology results (H.R. 0.537, 95% C.I. 0.388 322 - 0.742, p-value 1.64×10^{-4} , H.R. 0.439, 95% C.I. 0.272 - 0.710, p-value 7.85×10^{-4} and H.R. 0.0854, 323 95% C.I. 0.0298 - 0.245, p-value 4.79×10^{-6} , respectively). In the IPTW Kaplan-Meier analysis, we 324 found that treatment concordance with the OncoNPC prediction was associated with Gastrointesti-325 nal (GI) cancer types (coefficient 1.916, 95% C.I. 0.627 - 3.205, p-value 3.57×10^{-3}), whereas male 326 sex and OncoNPC prediction uncertainty (i.e., entropy of predicted probability distribution over the 327 considered cancer types) were inversely associated with receiving concordant treatment (coefficient 328 -1.259, 95% C.I. -2.283 - 0.234, p-value 1.61×10^{-2} , and coefficient -1.693, 95% C.I. -2.458 - 0.927, 329 p-value 1.46×10^{-5}) (see Supplementary Fig. S8). These associations with treatment concordance are 330 consistent with likely GI CUPs being more clinically identifiable and low OncoNPC confidence CUPs 331 being less clinically identifiable. We note, however, that the IPTW approach specifically adjusts for 332 these systematic differences when estimating the effect of treatment concordance on survival. 333

334 Discussion

Our work provides unique insights into the genetic and prognostic landscapes of CUP tumor samples by utilizing routinely collected EHR and multicenter NGS tumor panel sequencing data. We have developed OncoNPC, a machine learning model for molecular classification of tumor samples based on the NGS panel data. When evaluated with the held-out multicenter test data, OncoNPC provided

It is made available under a CC-BY 4.0 International license .

robust and interpretable predictions. Applying OncoNPC to CUP tumor samples, we demonstrated 339 that the OncoNPC CUP subtypes showed significantly higher germline PRS risk for their predicted 340 cancer. To our knowledge, this is the first evidence of germline genetic correlation between CUPs 341 and corresponding known primaries, and lends orthogonal support to the molecular classification of 342 CUPs into subtypes. We demonstrated clinical utility of the OncoNPC CUP subtypes by showing 343 significant survival differences across subtypes, and, within subtypes, potentially actionable somatic 344 alterations in 11.5% (Level 1 therapeutic level) and 22.8% (all levels) of tumors. Finally, in a 345 retrospective analysis, we showed that patients with CUP, that had been treated in a consistent manner with their OncoNPC classification, achieved significantly longer survival than those treated 347 in an inconsistent manner (multivariable Cox regression: H.R. 0.348, 95% C.I. 0.210 - 0.570, p-value 348 2.32×10^{-5}). Our findings suggest that CUP tumors share a genetic and prognostic architecture with 349 known cancer types, and may benefit from molecular classification with OncoNPC for prognosis as 350 well as treatment decision-making. 351

The question of whether CUP tumors consist of heterogeneous latent primaries or are a unique 352 cancer type in and of themselves has been actively investigated [18, 45, 46]. Prior studies have 353 demonstrated accurate classification of known tumors using Whole-Genome Sequencing [12], NGS 354 panels [10], RNA-seq [11], methylation [8], and other platforms [47, 48]. However, these algorithms 355 typically applied classification to metastatic tumors of known types and did not investigate the 356 clinical implications for CUPs at large scale. Moran et al., [8] observed a nominally significant 357 difference in survival between patients with CUP who received site-specific treatments concordant 358 with their molecular primary site predictions and those who received empiric treatments. While 359 promising, it remains unknown whether this difference is due to accurate classification for the site-360 specific group or systematically worse outcomes for the empirically treated group, which is typically 361 a more challenging patient population [49]. To explicitly distinguish these scenarios, our analysis 362 instead restricted to a CUP cohort wherein all patients received site-specific treatments as the 363 first palliative-intent therapy and estimated a significant survival benefit of concordant treatment 364 discordant treatment (excluding the empirically treated group). Our findings were obtained 365 after adjusting for left-truncation for sequencing time and measured potential confounders through 366 covariate adjustment as well as propensity score weighting, which have been recently employed to 367 mimic clinical trials in Real World data [43, 44]. Although we cannot rule out potential biases from 368 unmeasured confounders, our cohort includes more heterogeneous populations compared to recruited 369 cohorts in randomized controlled trials (RCT), and the proposed intervention (concordant treatment 370 vs. discordant treatment) is challenging to ethically evaluate through RCTs, necessitating the use 371 of retrospective causal inference. 372

Our study has several limitations. Firstly, although we utilized multicenter NGS tumor panel sequencing data to train OncoNPC model for cancer type prediction, we utilized retrospective EHR data from a single institution for the downstream clinical analyses. As a result, these analyses may be susceptible to systematic ascertainment patterns or biases specific to a tertiary academic cancer center. Replication of our clinical findings in other institutions is thus necessary to generalize our results. Secondly, we considered only the 22 most common cancer types in the cohort as classification labels (68.1 % of all tumor samples at DFCI, and 69.9 % across all three centers). As a result, if a

It is made available under a CC-BY 4.0 International license .

CUP tumor sample harbors a distinct yet not modeled primary cancer type, then the tumor sample 380 will likely have high uncertainty in the prediction (see Supplementary Fig. S1b). Nevertheless, prior 381 work has shown that the majority of resolvable primary sites of CUP tumor samples were from 382 common cancers (e.g., lung, pancreas, and GI) [18], consistent with our findings. As more diverse 383 tumor samples are collected across multiple institutions, our model can be augmented to robustly 384 predict rare cancer types as well. Thirdly, our classifier and analyses relied on data from panel 385 sequencing assays targeting 300-500 genes, which are inherently only sensitive to coding mutations 386 and deep copy number alterations in the targeted genes. Other features captured by whole-genome 387 sequencing or molecular assays may thus achieve better classification performance. Our focus in this 388 work was on assays that are in routine clinical use as those are linked to Real World clinical data 389 and offer the most immediate translational potential. 390

Our findings strongly suggest that routinely collected targeted tumor panel sequencing data have 391 clinical utility in assisting diagnostic work-up and prognosis, and may additionally inform treatment 392 decisions. To date, clinical sequencing is primarily used for identification of known biomarkers and 393 corresponding clinical trial enrollment [50–53], and our findings additionally support use of panel 394 sequencing for diagnosis. Conventional IHC-based pathology reviews are often unable to identify a 395 primary diagnosis for advanced metastatic tumor samples [3, 6], particularly in community clinics 306 where resources are limited. And in many cases, patients do not receive the complete diagnostic 397 work-up that is recommended for CUPs [54]. As a result, oncologists resort to empiric treatment 398 regimens to treat many patients with CUP [18] even when targeted therapies would otherwise be 399 the standard of care for a corresponding known primary. In future work, we envision a multimodal 400 framework that incorporates molecular sequencing together with patient pathology images [48], 401 physiological data, and clinical notes to directly predict optimal treatment regiments rather than 402 just cancer types. Our work thus paves a way for incorporating routine panel sequencing data into 403 clinical decision support tools for clinically challenging cases. 404

405 Methods

⁴⁰⁶ Patients and tumor samples

We used the next generation sequencing (NGS) targeted panel sequencing data collected at three 407 institutions in routine clinical care as part of the AACR project GENIE [1]: Dana-Farber Can-408 cer Institute (DFCI, n=18,816), Memorial Sloan Kettering Cancer (MSK, n=16,294) center, and 409 Vanderbilt-Ingram Cancer Center (VICC, n=1,335). The collected tumor samples represented 22 410 different cancer types and included 971 total samples from cancer of unknown primary (CUP). Na-411 tional Death Index (NDI) and clinical death and last clinical appointment records were available 412 for 20,281 DFCI patients (n = 16,376 for CKP and n = 838 for CUP). Demographic details of the 413 patients and tumor samples can be found in Table 1. 414

The cancer centers, DFCI, MSK, and VICC, were chosen because of similar genomic data characterization of their sequence panels in terms of coverage and alteration types [1]. DFCI samples were sequenced using a custom, hybridization-based panel called OncoPanel which targeted exons of

It is made available under a CC-BY 4.0 International license .

275-447 genes across three panel versions [1, 52]. MSK samples were sequenced using a custom panel
called MSK-IMPACT which targeted 341-468 genes across 3 panel versions [1, 51]. VICC samples
were sequenced using custom panels called VICC-01-T5A and VICC-01-T7, which targeted 322 and
429 genes, respectively [1]. All panels were capable of detecting single nucleotide variants (SNVs),
small indels, copy number alterations, and structural variants [1].

The DFCI CUP cohort consisted of 971 sequenced tumor samples (from 962 patients) with a cancer diagnosis of CUP and the following detailed cancer type: Adenocarcinoma, Not Otherwise Specified (NOS) (n = 345), Cancer of Unknown Primary, NOS (n = 194), Squamous Cell Carcinoma, NOS (n = 114), Poorly Differentiated Carcinoma, NOS (n = 118), Neuroendocrine Tumor/Carcinoma, NOS (n = 170), Small Cell Carcinoma of Unknown Primary (n = 16), Undifferentiated Malignant Neoplasm (n = 12), and Mixed Cancer Types (n = 2). For downstream clinical analyses, we applied additional exclusion criteria, described in Supplementary Fig. S5.

⁴³⁰ Developing OncoNPC cancer type classifier

We used a gradient tree boosting framework (XGBoost [55]) to develop OncoNPC for predicting 431 cancer types from molecular features. In this framework, decision trees for the input features are 432 sequentially added to an existing ensemble of the trees, such that the algorithm fits the new tree to 433 the residuals from the ensembles with regularization on the tree structure. As the trees (a.k.a. weak 434 learners) are added, the model learns optimal weights to combine their predictions and produces the 435 improved outcome from the combined ensemble [55]. Owing to its high performance and scalability, 436 the XGBoost method has been used across a wide range of applications in the healthcare space 437 [56-58].438

OncoNPC was trained and evaluated using tumors from 22 known cancer types split into 29,176 439 training samples and 7.289 test samples. Hyper-parameter selection was conducted using random 440 search [59] with 10-fold cross validation within the training set while utilizing weighted F1 score as an 441 evaluation metric. The optimal hyper-parameters were then selected and the model was evaluated 442 on the held-out test set (n = 7.289). To predict primary sites of CUP tumors, the model was 443 then re-trained on all CKP tumor samples and applied to the CUP tumors to estimate posterior 444 probabilities across the 22 different cancer labels. For each tumor sample, a cancer type with the 445 highest probability was chosen as the predicted primary site. 446

⁴⁴⁷ Feature selection and OncoNPC model interpretation

The OncoNPC model was trained on somatic variant features from tumor sequencing data, as 448 well as patient age at sequencing and sex. Other demographic/clinical features were intentionally 449 not used so as not to bias the model toward cancer types with more available information. Somatic 450 variant features included: mutations (i.e., single nucleotide variants (SNV) and indels), Copy Number 451 Alteration (CNA) events, and mutational signatures [60]. For each gene, the total count of a somatic 452 mutation (i.e., single nucleotide variants and indels) was encoded as a positive integer feature. The 453 presence of a CNA event for each gene was encoded as a categorical variable with 5 levels: -2 (deep 454 loss), -1 (single-copy loss), 0 (no event), 1 (low-level gain), and 2 (high-level amplification); note 455

It is made available under a CC-BY 4.0 International license .

that CNA events data for tumor samples from MSK and VICC were encoded as -2 (deep loss), 0
(no event), and 2 (high-level amplification). Each of 60 different mutation signatures was inferred as
the dot product of the weights derived from [60] and 96 single base substitutions in a trinucleotide
context. The single base substitutions were computed using the deconstructSigs R library [61].
See Supplementary Table S1 for the full set of features.

To identify important features in the OncoNPC's predictions, we used the recently proposed 461 feature interpretation tool for tree-based models, called TreeExplainer [19] (Python package shap). 462 TreeExplainer uses an efficient polynomial time algorithm $(O(TLD^2), T :$ number of trees, L: 463 number of leaves, D: maximum depth) to approximate Shapley values which capture the impact 464 of each feature on each individual model prediction. The Shapley value assigned to each feature 465 is modeled as the average change in the model's conditional expectation function over all possible 466 feature orderings when introducing the corresponding feature into the model; it is formulated as 467 $\mathbb{E}_{S}[f(X)|do(X_{S} = x_{S})]$, where S is the set of features, X is a random variable for the feature to 468 perturb, and do notation [62] reflects the causal feature perturbation formulation. See [19] for more 469 details on the algorithm and its properties. 470

Applying TreeExplainer on the model outcome at each fold across the 10-fold cross-fitting procedure, we obtained out-of-sample local explanations for all individual model predictions of primary cancer types. By combining local explanations of correct predictions for each cancer type, we characterized the cancer type in terms of the most important or predictive features based on their Shapley values, which provided insights into the somatic variants and clinical features most relevant to the classification of each cancer type.

477 Germline PRS-based validation on CUP tumor samples

To validate the OncoNPC predictions for CUP tumor samples (which do not otherwise have a ground 478 truth), we utilized germline Polygenic Risk Scores (PRS) which were never available to OncoNPC 479 for training. Germline imputation from the off-target tumor sequencing data was conducted as 480 previously described in [63]. Using weights from external GWAS data, we imputed PRS for Non-481 Small Cell Lung Cancer (NSCLC), Invasive Breast Carcinoma (BRCA), Colorectal Adenocarcinoma 482 (COADREAD), Diffuse Glioma (DIFG), Melanoma (MEL), Ovarian Epithelial Tumor (OVT), Renal 483 Cell Carcinoma (RCC), and Prostate Adenocarcinoma (PRAD). Pearson correlation between the 484 PRS from off-target tumor data versus matched germline SNP array was previously shown to be 485 higher than 0.9 without observable outliers [63]. 486

We hypothesized that germline PRS specific to the underlying primary cancer type of a CUP tumor sample would be enriched in a manner similar to how the PRS specific to CKP tumor sample with the same primary cancer type is enriched. To that end, given the set of 8 different cancer types C we have the imputed PRS available for, we first restricted the cohort of CUP tumor samples to those with OncoNPC predictions in C ($N_{\text{CUP},C} = 505$). Then, we obtained standardized germline PRS values for the chosen CUP tumor samples over all the cancer types in C. Finally, we defined $\hat{\Delta}_{\text{PRS}}$ as the estimated mean difference between the PRS specific to the predicted primary cancer type C (i.e. concordant PRS; PRS_C) and average of PRSs corresponding to the rest of the cancer

It is made available under a CC-BY 4.0 International license .

495 types (i.e. discordant PRS; PRS_D , where $D \in C \setminus C$) as follows

$$\hat{\Delta}_{\text{PRS}} = \hat{\mathbb{E}}[\text{PRS}_C - \hat{\mathbb{E}}_D[\text{PRS}_D|C]] = \frac{1}{N_{\text{CUP},\mathcal{C}}} \sum_{i}^{N_{\text{CUP},\mathcal{C}}} (\text{PRS}_{c_i} - \frac{1}{|\mathcal{C} \smallsetminus c_i|} \sum_{d_i \in \mathcal{C} \smallsetminus C_i} \text{PRS}_{d_i})$$
(1)

As a true positive reference, we repeated the above procedure for the CKP tumor samples. Finally, as a true negative null, we estimated $\hat{\Delta}_{PRS-random}$, where the concordant cancer type was randomly assigned. We then repeated the random assignment 100 times to obtain estimated mean and standard errors.

⁵⁰⁰ Survival function estimation

National Death Index (NDI) and in-house clinical records were available for 20,281 DFCI patients (n = 16,376 for CKP and n = 838 for CUP). A patient's lost to follow-up date was determined at either the last NDI update date (12/31/2020) or their corresponding last contact date from the in-house records, whichever date is later. A patient's death date was determined from the in-house records, or the NDI data if the patient was lost to follow-up.

506 CUP-metastatic CKP survival comparison

We estimated median survival times of patients across CUP - metastatic CKP pairs using the 507 Kaplan-Meier estimator [64] to account for patients lost to follow-up. For the CUP cohort, we 508 excluded patients with CUP that were lost to follow up at the time of tumor sequencing and those 509 whose primary cancer types were predicted with low probability (see Supplementary Fig. S5). The 510 resulting CUP cohort (n = 685), was then restricted to OncoNPCcancer types with more than 511 35 CUP patients. For the CKP metastatic cohort, we excluded patients lost to follow up at the 512 tumor sequencing time in the same manner and chose patients with one of the known cancers, 513 where either the biopsy was metastatic or the patient had an ICD-10 code indicative of secondary 514 malignant neoplasms within a year prior to sequencing dates. A total of 521 and 5,937 patients were 515 thus retained from the CUP cohort and metastatic CKP cohort, respectively: Non-Small Cell Lung 516 Cancer (NSCLC; n_{CUP} = 200, n_{met-CKP} = 1,559), Pancreatic Adenocarcinoma (PAAD; n_{CUP} = 80, 517 $n_{met-CKP} = 357$), Invasive Breast Carcinoma (BRCA; $n_{CUP} = 67$, $n_{met-CKP} = 1,656$), Colorectal 518 Adenocarcinoma (COADREAD; $n_{CUP} = 54$, $n_{met-CKP} = 1,198$), Head and Neck Squamous Cell 519 Carcinoma (HNSCC; n_{CUP} = 44, n_{met-CKP} = 216), Esophagogastric Adenocarcinoma (EGC; n_{CUP} 520 = 40, $n_{met-CKP}$ = 336), and Ovarian Epithelial Tumor (OVT; n_{CUP} = 36, $n_{met-CKP}$ = 615). Note 521 that patients with CUP, whose predicted cancer type is Gastrointestinal Neuroendocrine Tumors 522 $(GINET; n_{CUP} = 39, n_{CKP} = 118)$, were excluded due to the fact that the estimated survival function 523 for the CUP cohort never reached 50 percent. 524

⁵²⁵ OncoNPC-based risk stratification among patients with CUP

To identify OncoNPC CUP subtypes with significant prognostic differences, we estimated survival functions for 7 common OncoNPC subtypes with more than 35 CUP patients: NSCLC, PAAD, BRCA, HNSCC, EGC, GINET, and Pancreatic Neuroendocrine Tumor (PANET). Patients that

It is made available under a CC-BY 4.0 International license .

were lost to follow up at time of sequencing were again excluded, as were CUPs with an OncoNPC prediction probability lower than 0.5 (i.e., same criteria as the CUP - metastatic CKP survival comparison analysis). We merged subtypes with similar morphology and estimated survival functions: PAAD and EGC; GINET and PANET. To statistically test survival differences between these 5 groups, we utilized Chi-squared test with 4 degrees of freedom.

Identifying prognostic somatic variants shared in CUP-metastatic CKP pairs

To identify prognostic somatic variants shared between CUP/metastatic-CKP pairs, we again re-536 stricted to the 7 common OncoNPC subtypes with at least 35 CUP patients: NSCLC, PAAD, 537 BRCA, COADREAD, HNSCC, EGC, GINET, and OVT. For somatic variants, we utilized the same 538 processed features utilized in the OncoNPC model training (see Methods: Feature selection and 539 OncoNPC model interpretation). To ensure sufficient statistical power, we restricted to candidate 540 somatic variants (i.e., mutated genes and CNA genes) present in at least 15 samples in a given On-541 coNPC subtype and corresponding metastatic CKP cohort, as well as all 96 mutational signatures. 542 After selecting the cancer types to consider in the CUP-metastatic CKP pairs and candidate somatic variants for each pair, we iteratively tested each feature for association with survival in 544 each OncoNPC subtype and in each corresponding metastatic CKP cohort. A multivariable Cox 545 Proportional Hazard regression [41] model was used with time-to-death from sequencing as the 546 outcome. To adjust for baseline effects, we included age at sequencing, sex, tumor sequencing panel 547 version, mutational burden (i.e., sum of total somatic mutations in each tumor sample), and CNA 548 burden (i.e., sum of total CNA events in each tumor sample) as covariates. Finally, to identify shared prognostic somatic variants for each CUP-metastatic CKP pair, we retained somatic variants 550 which passed Schoenfield residuals-based proportional hazard tests (lifelines Python library [65]: 551 p-value threshold: 0.05) and were nominally significant (p < 0.05) for both CUP and CKP cancer 552 types in each pair. 553

⁵⁵⁴ Actionable somatic variants in CUP tumors

We estimated the frequency of known, actionable somatic alterations in each OncoNPC CUP subtype 555 using the OncoKB knowledge base [38]. OncoNPC CUP predictions with a probability greater than 556 0.5 were retained (see Supplementary Fig. S5). We considered 3 different types for somatic variants: 557 oncogenic mutations such as indels, missense mutations, and splice site mutations, amplifications 558 such as high-level amplifications, and finally fusions such as gene-gene and gene-intergenic fusions as 559 specified in OncoKB. For each actionable somatic variant, we assigned one of the four therapeutic 560 levels: level 1 for FDA-approved drugs, level 2 for standard care drugs, level 3 for drugs supported 561 by clinical evidence, and level 4 for drugs supported by biological evidence. 562

It is made available under a CC-BY 4.0 International license .

Estimating impacts of treatment concordance on survival of patients with CUP

We estimated the impact of the concordance between treatment and OncoNPC CUP predictions on 565 a mortality outcome in a retrospective survival analysis. We utilized the in-house patient follow-up 566 and treatment data to identify patients with CUP who received first treatment at DFCI with a 567 palliative intent (Supplementary Fig. S5 for the exclusion criteria). Each patient was reviewed by a trained oncologist to determine whether the OncoNPC predicted cancer type was concordant or 569 discordant with the first line of treatment received, per National Comprehensive Cancer Network 570 (NCCN) guidelines or standard of care, in most reasonable situations, and within the clinical context 571 delineated in the medical record. See Supplementary Section: Determining treatment-OncoNPC 572 concordance for more details, and Supplementary Table S3 for clinical information, including primary 573 cancer diagnosis, biopsy site, and first chemotherapy plan at DFCI, of patients with CUP in the 574 analysis. 575

As we were interested in the counterfactual causal impact of the OncoNPC-treatment concordance, we utilized the principles of causal inference to account for potential patient heterogeneity and confounding. Specifically, we estimated the effect of treatment concordance specified by the indicator variable, A, which was 1 when the first palliative treatment for a patient with CUP was concordant with the corresponding OncoNPC prediction and 0 otherwise. Our analyses make the following identifiability assumptions:

- Conditional ignorability : $A_i \perp T_i^{a_i} | X_i$, where $A_i \in 0, 1$. It means that given patient *i*'s a set of covariates X_i , the patient's treatment concordance A_i is as good as random.
- Consistency : $T_i^{a_i} = T_i$, which means that a counterfactual outcome $T_i^{a_i}$ for patient *i* is the observed outcome for the patient with a treatment concordance a_i .
- Overlap : $P(0 < p(X_i) < 1) = 1$ where $p(X_i) = P(A_i = 1|X_i)$, which means all patients have a strictly positive probability for receiving concordant treatment $(A_i = 1)$.
- In addition to the above identifiability assumptions, we made independent censoring (i.e. $C_i \perp T_i | X_i$) and independent entry assumption given the covariates (i.e. $E_i \perp T_i | X_i$).

We adopted two different estimation strategies to obtain the impact of treatment concordance: 590 semi-parametric Cox Proportional Hazard estimator adjusted with a set of measured confounders 591 X [41] and non-parametric Kaplan Meier estimator adjusted with Inverse Probability Treatment 592 Weighting (IPTW). We formulated an IPTW, w_i for each sample as $w_i = \frac{P(A=a_i)}{P(A_i=a_i|X_i)}$ [42] and 593 estimated P(A) non-parametrically and P(A|X) using a logistic regression model (R glm package 594 [66]) in a 10-fold cross-fitting. A set of measured confounders (i.e., X_i) included patients' sex, 595 age, OncoNPC prediction uncertainty (in entropy of posterior distribution over 22 cancer types), 596 sequencing panel (i.e., OncoPanel) version, mutational burden, CNA burden, subsets of OncoNPC 597 predicted cancer types and metastasis sites, and finally pathological histology (e.g., adenocarcinoma 598 tumor or neuroendocrine tumor). Since patients with CUP who met the treatment criteria (i.e., 599 follow-up start time) but did not receive clinical panel sequencing (i.e., entry time) could not be 600

It is made available under a CC-BY 4.0 International license .

included in the analysis, we adjusted for the left truncation by defining the risk set $\mathcal{R}(t)$ at time t, which corresponds to the set of patients followed up in the analysis up to time t as follows

$$\mathcal{R}(t) = \{i | E_i \le t \le T_i\}$$

, where E_i is the entry time of patient *i*. With the independent entry assumption as stated before, we obtained survival function from Kaplan-Meier estimator as follows

$$\hat{S}(t) = \prod_{i:T_i \le t} \left(1 - \frac{\sum_{k:T_k = T_i} w_k}{\sum_{j:j \in \mathcal{R}(T_i)} w_j} \right)$$

In this formulation, each individual is weighted by the corresponding IPTW, w_i , and we obtained two different survival functions for the treatment concordant and discordant groups. The adjusted Kaplan-Meier estimator provides a consistent estimate of impact of the treatment concordance under the assumptions stated above [42]. Once we obtained the survival estimates for the two groups, we used a weighted log-rank test [67] to test for a significant difference in survival.

In the Cox proportional hazard regression framework, we estimated the hazard function of patient *i* as follows: $\lambda(t|A_i, X_i) = \lambda_0(t) \exp(\alpha A_i + \beta^T X_i)$, where $\alpha, A_i \in \mathbb{R}$ and $\beta, X_i \in \mathbb{R}^m$ (*m* is the number of measured confounders). Under the above identifiability assumptions and validity of the estimation model, e^{α} is the hazard ratio capturing the causal effect of the treatment concordance *A*. Finally, under the assumption of no ties between event times across the patients, the parameters α and β are estimated by maximizing the following partial likelihood

$$L(\alpha,\beta) = \prod_{i:\delta_i=1} \frac{\exp(\alpha A_i + \beta X_i)}{\sum_{j:j\in\mathcal{R}(T_i)} \exp(\alpha A_j + \beta X_j)}$$

616 [41].

Acknowledgments

The participation of patients and the efforts of an institutional data collection system made this study possible, and we are grateful for their contributions. We would also like to express our appreciation to the DFCI Oncology Data Retrieval System (OncDRS) and AACR Project GENIE team for their role in aggregating, managing, and delivering the data used in this project.

622 Funding

IM and AG were supported by R01 CA227237, R01 CA244569, as well as grants from The Louis

B. Mayer Foundation, The Doris Duke Charitable Foundation, The Phi Beta Psi Sorority, and The
 Emerson Collective.

It is made available under a CC-BY 4.0 International license .

⁶²⁶ Supplementary Note

627 Determining treatment-OncoNPC concordance

Concordance of OncoNPC predicted cancer type with a first palliative treatment assignments at 628 DFCI was classified in one of five categories: 1) "TRUE": the OncoNPC cancer type matched 629 the clinically proven/suspected tumor type and the predicted treatment matched the treatment 630 received, which was dictated by NCCN guidelines and/or standard of care, within the clinical context 631 provided by the medical record; 2) "FALSE": the OncoNPC cancer type did not match the clinically 632 proven/suspected cancer type and the predicted treatment was not appropriate per NCCN guidelines 633 or standard of care, in most reasonable situations, and within the context of the medical record; 3) 634 "SOFT FALSE": the OncoNPC cancer type did not match the clinically proven/suspected cancer 635 type, but the treatment received was not chosen based on NCCN guidelines or standard of care, owing 636 to the unique clinical context provided by the medical record, 4) "EMPIRIC": treatment received was 637 empiric treatment for cancer of unknown primary (e.g., carboplatin/taxol or gemcitabine/cisplatin) 638 with the corresponding clinical rationale; in cases where patients received these regimens but not 639 with the clinical intent of empiric CUP treatment (i.e., as regimens intended for treating other tumor 640 types), the predicted treatment was not labeled as "EMPIRIC" and the case was instead evaluated 641 in context of the proven/suspected tumor type. In our analysis, we considered the TRUE group 642 as the concordant group, and FALSE and SOFT FALSE groups as the discordant group. We did 643 not include the EMPIRIC group, which is typically a more challenging patient population with 644 systematically worse outcomes [49].

646 Code Availability

⁶⁴⁷ Please see https://github.com/itmoon7/onconpc for the pre-processing script, the trained OncoNPC

model, and other reference materials.

It is made available under a CC-BY 4.0 International license .

⁶⁴⁰ Figure and Table Legends

Figure 1. Overview of model development and analysis workflow. (a) OncoNPC, a 650 XGBoost-based classifier, was trained and evaluated using 36,729 tumor samples across 22 cancer 651 types from Cancers of Known Primary (CKP) collected from three different cancer centers. (b) 652 OncoNPC performance was evaluated on the held-out tumor samples (n = 7,289). (c) OncoNPC 653 was applied to 971 CUPs at a single institution to predict primary cancer types. OncoNPC pre-654 dicted CUP subtypes were then investigated for association with: (d) elevated germline risk, (e) 655 actionable molecular alterations, (f) overall survival, and (g) prognostic somatic features. (h) A 656 subset of CUP patients with detailed treatment data were evaluated for treatment-specific outcomes. 657

Figure 2. Cancer type prediction performance of OncoNPC. (a),(b) The normalized con-659 fusion matrix of OncoNPC classification performance on the held-out test set (n = 7,289) for (a) 660 22 detailed cancer types and (b) 10 broad cancer groups based on site and treatment (see Table 1). The sensitivity for each cancer type or cancer group is shown below each confusion matrix and the 662 sample size is shown to the left of each confusion matrix. (c), (d) The performance (by F1 score) 663 of OncoNPC on the test set across cancer types (c) and groups (d) at 4 different prediction confi-664 dences (i.e., minimum p_{max} thresholds). Each dot size is scaled by the proportion of tumor samples 665 retained. (e) Precision-recall curves showing the performance of the OncoNPC across different co-666 horts in the test set by: cancer center, biopsy site type, sequence panel version, and ethnicity (color 667 coded), with the vellow dotted curve corresponding to the baseline performance on the full test set. 668 669

Figure 3. Applying OncoNPC to CUP tumor samples and interpreting cancer type pre-670 dictions. (a) Empirical distributions of prediction probabilities for correctly predicted, held-out 671 CKP tumor samples (n = 3,429) and CUP tumor samples (n = 934) across CKP cancer types (blue) 672 and their corresponding OncoNPC predicted cancer types for CUP tumors (green). Only OncoNPC 673 classifications with at least 20 CUP tumor samples are shown. (b) Proportion of each CKP cancer 674 type and the corresponding OncoNPC predicted CUP cancer type. All training CKP tumor samples 675 (n = 36,445) and all held-out CUP tumor samples (n = 971) are shown. For both (a) and (b), the 676 cancer types (x-axis) are ordered by the number of CKP tumor samples in each cancer type. (c) 677 Germline Polygenic Risk Score (PRS) enrichment of the CKP tumor samples (n = 11,332) and CUP 678 tumor samples with available PRS data (n = 505) averaged across 8 cancer types. The magnitude of 679 the enrichment is quantified by $\hat{\Delta}_{PRS}$: the mean difference between the concordant (i.e. OncoNPC 680 matching) cancer type PRS and mean of PRSs of discordant cancer types (see Methods). $\hat{\Delta}_{PRS}$ 681 is shown for CKPs in blue (for reference) and CUPs in green. As a negative control, $\hat{\Delta}_{PRS-random}$ 682 is also shown after permuting the OncoNPC labels. (d) Top 15 most important features based on 683 mean absolute SHAP values (i.e., $\hat{\mu}(|\text{SHAP}|)$ [19]) for the top 3 most frequent cancer types in the 684 cohort: Non-Small Cell Lung Cancer (NSCLC), Invasive Breast Carcinoma (BRCA), and Pancre-685 atic Adenocarcinoma (PAAD). The carrier rate for each feature in corresponding CKP and CUP 686 cancer cohorts as well as the entire CKP and CUP cohorts are shown as bars going downwards 687 and star-shaped markers, respectively. For mutation signature features that have continuous values, 688

It is made available under a CC-BY 4.0 International license .

individuals with feature values one standard deviation above the mean were treated as positives and
the rest as negative. For age, individuals above the population mean were treated as positives and
the rest as negatives. (e) Explanation of OncoNPC cancer type prediction for a sample patient with
CUP. The patient is a 76 year-old male, with a tumor biopsy from the liver. The pie chart on the
left shows the Top 10 important features across three different feature categories (i.e., CNA events,
somatic mutation, and mutation signatures), and the scatter plot on the right shows their SHAP
values and feature values. The size of each dot is scaled by corresponding absolute SHAP value.

696

Figure 4. Consistent survival and prognostic biomarkers between OncoNPC classifi-697 cations and known cancers. (a) Survival stratification for patients with CUP based on their 698 OncoNPC predicted cancer types. The Kaplan-Meier estimator [64] was used to estimate survival 699 probability for each predicted cancer type over the follow-up time of 60 months from sequence date. 700 with statistical significance assessed by Chi-square test. (b) Correspondence between median sur-701 vival time (in months) of CUP predicted cancer types (x-axis) and those of metastatic CKP cancer 702 types (y-axis): Spearman's rho 0.964 (p-value: 4.54×10^{-4}). The size of each dot reflects the p-value 703 of log-rank test for significant difference in median survival between CUP - metastatic CKP pairs. 704 Only cancer types with at least 30 CUP tumor samples having OncoNPC probabilities greater than 705 0.5 are shown. (c), (d) Prognostic somatic variants significantly associated with overall survival, 706 shared between three different CUP (c)-metastatic CKP (d) pairs (NSCLC, PAAD, and COAD-707 READ; indicated by point shape). Variant types are indicated by colors: red for somatic mutations, 708 green for CNAs, and blue for mutation signatures. 709

710

Figure 5. Potential for clinical decision support among OncoNPC classified CUPs. (a) 711 The number of CUP tumor samples with actionable targets, based on OncoKB [38], across actionable 712 somatic variants (mutations, amplifications, and fusions). Each bar corresponds to an actionable 713 target, color-coded by the number of each OncoNPC classified CUP carrier. Note that each tumor 714 sample may contain more than one actionable somatic variant. (b) Proportions of CUP tumor 715 samples with actionable somatic variants (N_{action}) to the total number of patients (N_{total}) across 716 OncoNPC predicted cancer types. Proportions for 4 different therapeutic levels based on OncoKB 717 [38], are shown in each bar: Level 1 - FDA-approved drugs, Level 2 – standard of care drugs, Level 718 3 - drugs supported by clinical evidence, and Level 4 - drugs supported by biological evidence. (c), 719 (d) Treatment diagrams for a group of patients with CUP who received treatments that were concor-720 dant with the OncoNPC classification (c) and the remaining CUP patients who received discordant 721 treatments (d). OncoNPC classification is shown on the left and treatment groups are shown on 722 the right, with each patient connected from left to right. (e) Forest plot of a multivariable Cox 723 Proportional Hazards Regression on patients in the CUP cohort with first-line palliative treatment 724 records at DFCI (n = 159; see Appendix Fig. S5 for the exclusion criteria). Treatment concordance 725 (colored in blue), encoded as 1 when the first treatment a patient received at DFCI is concordant 726 with their corresponding OncoNPC prediction and 0 otherwise, was significantly associated with 727 mortality of patients in the cohort (H.R. 0.321, 95% C.I. 0.165 - 0.620, p-value: < 0.001). (f) 728 Estimated survival curves for patients with CUP in the concordant treatment group (shown in blue) 729

It is made available under a CC-BY 4.0 International license .

and discordant treatment group (shown in red), respectively. To estimate the survival function for
each group, we utilized Inverse Probability of Treatment Weighted (IPTW) Kaplan-Meier estimator

while adjusting for left truncation until time of sequencing (see Methods). Statistical significance of

- ⁷³³ the survival difference between the two groups was estimated by a weighted log-rank test [68].
- the survival difference between the two groups was estimated by a weighted log-rank test [68].
- 734

Table 1. Demographic details of the patients and tumor samples across DFCI, MSK, and VICC.

736

Table 2. Demographic details of patients wit CUP in the concordant and discordant treatmentgroups.

739

Supplementary Figure S1. OncoNPC prediction performances and confidences (i.e., 740 p_{max}) across centers. (a) Center-specific OncoNPC performance (in weighted F1) on the test 741 CKP tumor samples (n = 7,289). The figure is a decomposed version of Fig. 2c by cancer center 742 $(DFCI: \bigcirc, MSK: \Box, VICC: \diamondsuit)$. The performance was evaluated at 4 different prediction confidences 743 (i.e., minimum p_{max} thresholds). Each dot size is scaled by the proportion of tumor samples re-744 tained. See Table S2 for the center-specific number of test CKP tumor samples across cancer types. 745 (b), (c) Box plots of prediction confidences (p_{max}) across (b) DFCI CUP tumors, MSK CUP tu-746 mors, all DFCI CKP tumors, DFCI held-out CKP tumors, and DFCI excluded CKP tumors, and 747 (c) DFCI held-out CKP tumors, MSK held-out CKP tumors, and VICC held-out CKP tumors. 748 Medians and lower and upper quartiles are shown on the figures along with corresponding number 749 of tumor samples as well as means and 95% confidence intervals. 750

751

⁷⁵² Supplementary Figure S2. Interpreting OncoNPC predictions. Top 15 most important ⁷⁵³ features based on mean absolute SHAP values (i.e., $\hat{\mu}(|\text{SHAP}|)$ [19]) for cancer types with at least ⁷⁵⁴ 20 CUP tumors samples were classified into.

755

Supplementary Figure S3. SHAP summary plot [19] for cancer types with at least 20 CUP
tumors samples were classified into. SAHP values (i.e., impact on OncoNPC predictions) are shown
on the x-axis, while features values are shown with a color map (from purple to yellow). In each
plot, CUP and CKP tumor samples were combined into one cohort for the corresponding cancer.

Supplementary Figure S4. Applying OncoNPC to MSK CUP tumor samples. (a) Em-761 pirical distributions of prediction probabilities for correctly predicted, held-out CKP tumor samples 762 (n = 3,429) and MSK CUP tumor samples (n = 496) across CKP cancer types (blue) and their 763 corresponding OncoNPC predicted cancer types for CUP tumors (green). Only OncoNPC classifi-764 cations with at least 20 CUP tumor samples are shown. (b) Proportion of each CKP cancer type 765 and the corresponding OncoNPC predicted CUP cancer type. All training CKP tumor samples (n 766 = 36,445) and all MSK CUP tumor samples (n = 581) are shown. For both (a) and (b), the cancer 767 types (x-axis) are ordered by the number of CKP tumor samples in each cancer type. 768

769

770 Supplementary Figure S5. Exclusion criteria for downstream clinical analyses.

It is made available under a CC-BY 4.0 International license .

771

Supplementary Figure S6. Germline Polygenic Risk Score (PRS) enrichment of CKP tumor samples and CUP tumor samples across 8 different cancer types: (a) Colorectal Adenocarcinoma (COADREAD), (b) Diffuse Glioma (DIFG), (c) Invasive Breast Carcinoma (BRCA), (d) Melanoma (MEL), (e) Non-Small Cell Lung Cancer (NSCLC), (f) Ovarian Epithelial Tumor (OVT), (g) Prostate Adenocarcinoma (PRAD), and (h) Renal Cell Carcinoma (RCC). The magnitude of the enrichment is quantified by $\hat{\Delta}_{PRS}$: the mean difference between the concordant (i.e. OncoNPC matching) cancer type PRS and mean of PRSs of discordant cancer types (see Methods). $\hat{\Delta}_{PRS}$ is shown for CKPs in blue (for reference) and CUPs in green.

780

Supplementary Figure S7. Estimated survival curves for patients with CUP, broken down by 781 OncoNPC predicted cancer types: (a) BRCA, (b) Gastrointestinal (GI) group (CHOL, COAD-782 READ, EGC, and PAAD), (c) Lung (NSCLC and PLMESO), and (d) other OncoNPC cancer 783 types (BLCA, DIFG, GINET, HNSCC, MEL, OVT, PANET, PRAD, RCC, and UCEC). In each 784 figure, the concordant treatment group and discordant treatment group are shown in blue and red, 785 respectively. To estimate the survival function for each group, we utilized Inverse Probability of 786 Treatment Weighted (IPTW) Kaplan-Meier estimator while adjusting for left truncation until time 787 of sequencing (see Methods). Statistical significance of the survival difference between the two groups 788 was estimated by a weighted log-rank test [68]. 789

790

⁷⁹¹ Supplementary Figure S8. Summary of coefficients for estimating treatment-OncoNPC

concordance. Formally, we estimated out-of-sample P(A|X), where A corresponds to the treatment-OncoNPC concordance, using a logistic regression model in a 10-fold cross-fitting. The coefficients were obtained from the first fold. See Methods: Estimating impacts of treatment concordance on survival of patients with CUP for more details.

796

Supplementary Table S1. A full set of 861 somatic input features for OncoNPC, abstracted from
the next generation NGS targeted panel sequencing data. The features belong to three different
categories (shown as columns of the table): somatic mutations (i.e., single nucleotide variants and
indels: 316 features), Copy Number Alterations (CNA: 491 features), and mutational signatures
(54 features). Note that we included patients' sex and age in addition to the somatic features. See
Methods for more details on how the features were encoded.

803

Supplementary Table S2. Center-specific number of held-out CKP tumor samples across cancer types and prediction confidence (i.e., p_{max}) thresholds.

806

So **Supplementary Table S3.** Clinical information of patient with CUP in the treatment concordance analysis (n = 158).

809

It is made available under a CC-BY 4.0 International license .

References

- [1] A. P. G. Consortium *et al.*, "Aacr project genie: Powering precision medicine through an international consortium," *Cancer discovery*, vol. 7, no. 8, pp. 818–831, 2017.
- [2] N. Pavlidis, H. Khaled, and R. Gaafar, "A mini review on cancer of unknown primary site: A clinical puzzle for the oncologists," *Journal of advanced research*, vol. 6, no. 3, pp. 375–382, 2015.
- [3] G. R. Varadhachary and M. N. Raber, "Cancer of unknown primary site," New England Journal
 of Medicine, vol. 371, no. 8, pp. 757–765, 2014.
- [4] D. M. Hyman *et al.*, "Vemurafenib in multiple nonmelanoma cancers with braf v600 mutations," *New England Journal of Medicine*, vol. 373, no. 8, pp. 726–736, 2015.
- I. D. Hainsworth and F. A. Greco, "Cancer of unknown primary site: New treatment paradigms in the era of precision medicine," *American Society of Clinical Oncology Educational Book*, vol. 38, pp. 20–25, 2018.
- [6] G. G. Anderson and L. M. Weiss, "Determining tissue of origin for metastatic cancers: Meta analysis and literature review of immunohistochemistry performance," *Applied Immunohisto- chemistry & Molecular Morphology*, vol. 18, no. 1, pp. 3–8, 2010.
- K. A. Oien and J. L. Dennis, "Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling," *Ann Oncol*, vol. 23 Suppl 10, pp. x271–277, Sep. 2012.
- [8] S. Moran *et al.*, "Epigenetic profiling to classify cancer of unknown primary: A multicentre, retrospective analysis," *The Lancet Oncology*, vol. 17, no. 10, pp. 1386–1395, 2016.
- [9] W. Jiao *et al.*, "A deep learning system can accurately classify primary and metastatic cancers
 based on patterns of passenger mutations," *bioRxiv*, p. 214 494, 2019.
- [10] A. Penson *et al.*, "Development of genome-derived tumor type prediction to inform clinical
 cancer care," *JAMA oncology*, vol. 6, no. 1, pp. 84–91, 2020.
- B. He *et al.*, "A neural network framework for predicting the tissue-of-origin of 15 common cancer types based on rna-seq data," *Frontiers in Bioengineering and Biotechnology*, vol. 8, p. 737, 2020.
- L. Nguyen, A. Van Hoeck, and E. Cuppen, "Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features," *Nature communications*, vol. 13, 2022.
- [13] J. D. Hainsworth *et al.*, "Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: A prospective trial of the sarah cannon research institute," *Journal of Clinical Oncology*, vol. 31, no. 2, pp. 217–223, 2013.
- H. Yoon *et al.*, "Gene expression profiling identifies responsive patients with cancer of unknown
 primary treated with carboplatin, paclitaxel, and everolimus: Ncctg n0871 (alliance)," Annals
 of Oncology, vol. 27, no. 2, pp. 339–344, 2016.

It is made available under a CC-BY 4.0 International license .

H. Hayashi *et al.*, "Site-specific and targeted therapy based on molecular profiling by next-generation sequencing for cancer of unknown primary site: A nonrandomized phase 2 clinical trial," *JAMA oncology*, vol. 6, no. 12, pp. 1931–1938, 2020.

- [16] H. Hayashi *et al.*, "Randomized phase ii trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site," *Journal of Clinical Oncology*, vol. 37, no. 7, pp. 570–579, 2019.
- A.-M. Conway, C. Mitchell, and N. Cook, "Challenge of the unknown: How can we improve clinical outcomes in cancer of unknown primary?" *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, vol. 37, no. 23, pp. 2089–2090, 2019.
- T. Bochtler and A. Krämer, "Does cancer of unknown primary (cup) truly exist as a distinct
 cancer entity?" *Frontiers in oncology*, vol. 9, p. 402, 2019.
- 859 [19] S. M. Lundberg *et al.*, "From local explanations to global understanding with explainable ai
 60 for trees," *Nature machine intelligence*, vol. 2, no. 1, pp. 56–67, 2020.
- ⁸⁶¹ [20] J. G. Tate *et al.*, "Cosmic: The catalogue of somatic mutations in cancer," *Nucleic acids* ⁸⁶² *research*, vol. 47, no. D1, pp. D941–D947, 2019.
- ⁸⁶³ [21] G. da Cunha Santos, F. A. Shepherd, and M. S. Tsao, "Egfr mutations and lung cancer,"
 ⁸⁶⁴ Annual Review of Pathology: Mechanisms of Disease, vol. 6, pp. 49–69, 2011.
- Y.-L. Zhang *et al.*, "The prevalence of egfr mutation in patients with non-small cell lung cancer:
 A systematic review and meta-analysis," *Oncotarget*, vol. 7, no. 48, p. 78 985, 2016.
- S. S. Hecht, "Tobacco smoke carcinogens and lung cancer," JNCI: Journal of the National
 Cancer Institute, vol. 91, no. 14, pp. 1194–1210, 1999.
- R. Mehra *et al.*, "Identification of gata3 as a breast cancer prognostic marker by global gene expression meta-analysis," *Cancer research*, vol. 65, no. 24, pp. 11259–11264, 2005.
- 871 [25] S. Elsheikh *et al.*, "Ccnd1 amplification and cyclin d1 expression in breast cancer and their
 relation with proteomic subgroups and patient outcome," *Breast cancer research and treatment*,
 873 vol. 109, no. 2, pp. 325–335, 2008.
- 874 [26] X. Liu, M. Jakubowski, and J. L. Hunt, "Kras gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis," *American journal of clinical*876 pathology, vol. 135, no. 2, pp. 245–252, 2011.
- B77 [27] D. Dinu *et al.*, "Prognostic significance of kras gene mutations in colorectal cancer-preliminary
 Study," *Journal of medicine and life*, vol. 7, no. 4, p. 581, 2014.
- R. Hayes, J. Van Nieuwenhuize, J. Raatgever, and F. Ten Kate, "Aflatoxin exposures in the industrial setting: An epidemiological study of mortality," *Food and Chemical Toxicology*, vol. 22,
 no. 1, pp. 39–43, 1984.
- [29] M. A. Ahmed Adam, Y. M. Tabana, K. B. Musa, and D. A. Sandai, "Effects of different mycotoxins on humans, cell genome and their involvement in cancer," *Oncology Reports*, vol. 37, no. 3, pp. 1321–1336, 2017.

It is made available under a CC-BY 4.0 International license .

- [30] S. Marchese, A. Polo, A. Ariano, S. Velotto, S. Costantini, and L. Severino, "Aflatoxin b1 and m1: Biological properties and their involvement in cancer development," *Toxins*, vol. 10, no. 6, p. 214, 2018.
- [31] P. M. Westcott and M. D. To, "The genetics and biology of kras in lung cancer," *Chinese journal of cancer*, vol. 32, no. 2, p. 63, 2013.
- [32] H. Adderley, F. H. Blackhall, and C. R. Lindsay, "Kras-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition," *EBioMedicine*, vol. 41, pp. 711–716, 2019.
- [33] A. M. Conway, C. Mitchell, E. Kilgour, G. Brady, C. Dive, and N. Cook, "Br J CancerMolecular
 characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the
 'U' out of 'CUP'," Br J Cancer, vol. 120, no. 2, pp. 141–153, Jan. 2019.
- [34] A. J. Schoenfeld *et al.*, "The genomic landscape of smarca4 alterations and associations with
 outcomes in patients with lung cancersmarca4 alterations in lung cancer," *Clinical Cancer Research*, vol. 26, no. 21, pp. 5701–5708, 2020.
- [35] S. Papillon-Cavanagh, P. Doshi, R. Dobrin, J. Szustakowski, and A. M. Walsh, "Stk11 and keap1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort," *ESMO open*, vol. 5, no. 2, e000706, 2020.
- [36] T. Takahashi *et al.*, "Mutations in keap1 are a potential prognostic factor in resected non-small
 cell lung cancer," *Journal of surgical oncology*, vol. 101, no. 6, pp. 500–506, 2010.
- [37] T. Berghmans *et al.*, "Thyroid transcription factor 1—a new prognostic factor in lung cancer:
 A meta-analysis," *Annals of oncology*, vol. 17, no. 11, pp. 1673–1676, 2006.
- [38] D. Chakravarty *et al.*, "Oncokb: A precision oncology knowledge base," *JCO precision oncology*, vol. 1, pp. 1–16, 2017.
- [39] P. M. Grambsch and T. M. Therneau, "Proportional hazards tests and diagnostics based on
 weighted residuals," *Biometrika*, vol. 81, no. 3, pp. 515–526, 1994.
- [40] L. Simms, H. Barraclough, and R. Govindan, "Biostatistics primer: What a clinician ought to know—prognostic and predictive factors," *Journal of Thoracic Oncology*, vol. 8, no. 6, pp. 808–813, 2013.
- [41] D. R. Cox, "Regression models and life-tables," Journal of the Royal Statistical Society: Series
 B (Methodological), vol. 34, no. 2, pp. 187–202, 1972.
- [42] J. Xie and C. Liu, "Adjusted kaplan-meier estimator and log-rank test with inverse probability of treatment weighting for survival data," *Statistics in medicine*, vol. 24, no. 20, pp. 3089–3110, 2005.
- [43] R. Liu *et al.*, "Systematic pan-cancer analysis of mutation-treatment interactions using large
 real-world clinicogenomics data," *Nature Medicine*, vol. 28, no. 8, pp. 1656–1661, 2022.
- [44] R. Liu *et al.*, "Evaluating eligibility criteria of oncology trials using real-world data and ai,"
 Nature, vol. 592, no. 7855, pp. 629–633, 2021.

It is made available under a CC-BY 4.0 International license .

- [45] S. Kolling *et al.*, ""metastatic cancer of unknown primary" or "primary metastatic cancer"?"
 Frontiers in Oncology, vol. 9, p. 1546, 2020.
- [46] T. Olivier et al., "Redefining cancer of unknown primary: Is precision medicine really shifting
 the paradigm?" Cancer treatment reviews, vol. 97, p. 102 204, 2021.
- [47] E. Moiso *et al.*, "Developmental deconvolution for classification of cancer origin," *medRxiv*, 2021.
- [48] M. Y. Lu *et al.*, "Ai-based pathology predicts origins for cancers of unknown primary," *Nature*, vol. 594, no. 7861, pp. 106–110, 2021.
- [49] K. Fizazi, F. Greco, N. Pavlidis, G. Daugaard, K. Oien, and G. Pentheroudakis, "Cancers of unknown primary site: Esmo clinical practice guidelines for diagnosis, treatment and follow-up," *Annals of Oncology*, vol. 26, pp. v133–v138, 2015.
- T. L. Stockley *et al.*, "Molecular profiling of advanced solid tumors and patient outcomes
 with genotype-matched clinical trials: The princess margaret impact/compact trial," *Genome medicine*, vol. 8, no. 1, pp. 1–12, 2016.
- D. T. Cheng *et al.*, "Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (msk-impact): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology," *The Journal of molecular diagnostics*, vol. 17, no. 3, pp. 251–264, 2015.
- E. P. Garcia *et al.*, "Validation of oncopanel: A targeted next-generation sequencing assay for
 the detection of somatic variants in cancer," *Archives of Pathology and Laboratory Medicine*,
 vol. 141, no. 6, pp. 751–758, 2017.
- ⁹⁴³ [53] D. Sha, Z. Jin, J. Budczies, K. Kluck, A. Stenzinger, and F. A. Sinicrope, "Tumor mutational
 ⁹⁴⁴ burden as a predictive biomarker in solid tumors," *Cancer discovery*, vol. 10, no. 12, pp. 1808–
 ⁹⁴⁵ 1825, 2020.
- L. Mileshkin *et al.*, "Cancer-of-unknown-primary-origin: A seer-medicare study of patterns of care and outcomes among elderly patients in clinical practice," *Cancers*, vol. 14, no. 12, p. 2905, 2022.
- [55] T. Chen and C. Guestrin, "Xgboost: A scalable tree boosting system," in *Proceedings of the*22nd acm sigkdd international conference on knowledge discovery and data mining, 2016,
 pp. 785–794.
- Y. Chen *et al.*, "Physiol MeasClassification of short single-lead electrocardiograms (ECGs) for atrial fibrillation detection using piecewise linear spline and XGBoost," *Physiol Meas*, vol. 39, no. 10, p. 104 006, Oct. 2018.
- [57] C. M. Hatton, L. W. Paton, D. McMillan, J. Cussens, S. Gilbody, and P. A. Tiffin, "Predicting persistent depressive symptoms in older adults: A machine learning approach to personalised mental healthcare," *Journal of affective disorders*, vol. 246, pp. 857–860, 2019.
- A. Ogunleye and Q.-G. Wang, "Xgboost model for chronic kidney disease diagnosis," *IEEE/ACM transactions on computational biology and bioinformatics*, vol. 17, no. 6, pp. 2131–2140, 2019.

It is made available under a CC-BY 4.0 International license .

- J. Bergstra and Y. Bengio, "Random search for hyper-parameter optimization.," Journal of
 machine learning research, vol. 13, no. 2, 2012.
- ⁹⁶² [60] L. B. Alexandrov *et al.*, "NatureThe repertoire of mutational signatures in human cancer,"
 ⁹⁶³ Nature, vol. 578, no. 7793, pp. 94–101, Feb. 2020.
- R. Rosenthal, N. McGranahan, J. Herrero, B. S. Taylor, and C. Swanton, "Genome BiolDeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution," *Genome Biol*, vol. 17, p. 31, Feb. 2016.
- ⁹⁶⁷ [62] D. Janzing, L. Minorics, and P. Blöbaum, "Feature relevance quantification in explainable ai: A causal problem," in *International Conference on artificial intelligence and statistics*, PMLR, 2020, pp. 2907–2916.
- A. Gusev, S. Groha, K. Taraszka, Y. R. Semenov, and N. Zaitlen, "Constructing germline research cohorts from the discarded reads of clinical tumor sequences," *Genome medicine*, vol. 13, no. 1, pp. 1–14, 2021.
- ⁹⁷³ [64] E. L. Kaplan and P. Meier, "Nonparametric estimation from incomplete observations," Journal
 of the American statistical association, vol. 53, no. 282, pp. 457–481, 1958.
- ⁹⁷⁵ [65] C. Davidson-Pilon, "Lifelines: Survival analysis in python," Journal of Open Source Software,
 ⁹⁷⁶ vol. 4, no. 40, p. 1317, 2019.
- ⁹⁷⁷ [66] I. Marschner, M. W. Donoghoe, and M. M. W. Donoghoe, "Package 'glm2'," *Journal, Vol*, vol. 3, no. 2, pp. 12–15, 2018.
- a. Pezzi, M. Cavo, A. Biggeri, E. Zamagni, and O. Nanni, "Inverse probability weighting to
 estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple
 myeloma," *BMC medical research methodology*, vol. 16, no. 1, pp. 1–10, 2016.
- [68] S. Xu *et al.*, "Extension of kaplan-meier methods in observational studies with time-varying treatment," *Value in Health*, vol. 15, no. 1, pp. 167–174, 2012.

Model evaluation and interpretation (b) Model performance evaluation Cancer centers Ethnicities Targeted clinical NGS assays : DFCI OncoPanel, MSK IMPACT, and VICC Panel Posterior probabilities across 22 cancer types (a) Somatic variants pre-processing Sample ID NSCLC PRAD Asian DFCI TS1 DECI - Other MSK VICC MSK TS1 - Spanish Hispania Somatic mutations: Copy number alterations Mutation signature DFCI TS2 (Overall) (Overall) SNVs & indels (CNA) 44 Recall Recall OncoNPC predictions for Sample ID held-out CKP tumors OncoNPC: XGBoost-based Model interpretation DFCI TS1 MSK TS1 primary cancer type classifier DFCI_TS CNA events Somatic OncoNPC predictions for Mutation CUP tumors (n = 36,465 tumor samples with known primary cancer types) TERT KRAS (c) Clinical utility of OncoNPC classifications for patients with CUP KEAP Age Age NKX2-1 Sex (e) Actionable molecular (f) Risk stratification among (g) (h) Effect of treatment Prognostic somatic variants patients with CUP concordance on prognosis alterations Mutation signature CUP predicted cancer types NSCLC D COADREAD PAAD Treatment target (d) Germline PRS validation for CUP tumor samples and prediction KRAS datation signature CHO Concordant STK11 NSCLO ~ PRF1 GWAS Polygen Scores (PRS) ,585106 Discordant PRAF 0.6 Time pet/Ntotal Time Hazard ratio Risk OncoKB precision Treatment plans In-house follow-up and clinical outcome database Prediction confidence oncology database database

Figure 1

Table 1 $\,$

		DFCI	MSK	VICC	DFCI CUP
	Number of patients	18,106	15,151	1,310	962
	Patients age at sequence (95 % C.I.)	60.7 (60.5 - 60.9)	60.2 (60.0 - 60.4)	58.3 (57.6 - 59.0)	61.9 (61.1 - 62.7)
	Sex; male-female ratio	43.8 - 56.2	43.5 - 56.5	44.5 - 55.5	50.0 - 50.0
		Patients ethnicity (pr	oportion %)		
	White	16,105 (88.9 %)	11,575 (76.4 %)	1,089 (83.1 %)	853 (88.7 %)
	Black	538 (3.0 %)	866 (5.7 %)	72 (5.5 %)	38 (4.0 %)
Asian Hispanic		554 (3.1 %)	956 (6.3 %)	17 (1.3 %)	34 (3.5 %)
		379 (2.1 %)	744 (4.9 %)	14 (1.1 %)	15 (1.6 %)
	Others	530 (2.9 %)	1010 (6.7 %)	118 (9.0 %)	22 (2.2 %)
		Sequenced Tumor	Samples		
	Total number of samples	18,816	16,294	1,335	971
		Panel version (proportion %; 95	% sequence date range)		
	vl	OncoPanel v1	MSK-IMPACT341	VICC-01-T5A	OncoPanel v1
	VI	1,924 (10.2 %; 2013-8-20 - 2014-8-17)	1,803 (11.1 %; Not available)	307 (23.0 %; Not available)	47 (4.8 %; 2013-9-8 - 2014-8-12)
	v2	OncoPanel v2	MSK-IMPACT410	VICC-01-T7	OncoPanel v2
		5,304 (28.2 %; 2014-9-28 - 2016-10-5)	6,917 (42.5 %; Not available)	1,028 (77.0 %; Not available)	203 (20.9 %; 2014-11-5 - 2016-10-5
	v3	OncoPanel v3	MSK-IMPACT468		OncoPanel v3
		11,588 (61.6 %; 2016-11-11 - 2021-1-6)	7,574 (46.5 %; Not available)		721 (74.3 %; 2016-12-14 - 2020-12-2
		Biopsy site t	ype		
	Primary	11,662 (62.0 %)	9,576 (58.8 %)	622 (46.6 %)	
	Metastatic recurrence	5,737 (30.5 %)	6,718 (41.2 %)	637 (47.7 %)	
	Local recurrence	673 (3.6 %)	Not available	64 (4.8 %)	
	Unspecified/others	744 (4.0 %)	Not available	12 (0.9 %)	
Cancer group	OncoTree Cancer type				Predicted cancer type
ung (Thoracic)	Non-Small Cell Lung Cancer (NSCLC)	3,489 (18.5 %)	3,183 (19.5 %)	137 (10.3 %)	280 (28.8 %)
	Pleural Mesothelioma (PLMESO)	258 (1.4 %)	118 (0.7 %)	2 (0.1 %)	9 (0.9 %)
	Colorectal Adenocarcinoma (COADREAD)	2,525 (13.4 %)	1,919 (11.8 %)	232 (17.4 %)	63 (6.5 %)
	Esophagogastric Adenocarcinoma (EGC)	988 (5.3 %)	495 (3.0 %)	59 (4.4 %)	69 (7.1 %)
astrointestinal	Pancreatic Adenocarcinoma (PAAD)	772 (4.1 %)	980 (6.0 %)	53 (4.0 %)	85 (8.8 %)
	Cholangiocarcinoma (CHOL)	241 (1.3 %)	338 (2.1 %)	44 (3.3 %)	33 (3.4 %)
	Gastrointestinal Neuroendocrine Tumors (GINET)	219 (1.2 %)	76 (0.5 %)	18 (1.3 %)	46 (4.7 %)
	Pancreatic Neuroendocrine Tumor (PANET)	121 (0.6 %)	133 (0.8 %)	12 (0.9 %)	23 (2.4 %)
Sarcoma	Gastrointestinal Stromal Tumor (GIST)	273 (1.5 %)	217 (1.3 %)	5 (0.4 %)	3 (0.3 %)
Iead and Neck	Head and Neck Squamous Cell Carcinoma (HNSCC)	473 (2.5 %)	285 (1.7 %)	20 (1.5 %)	52 (5.4 %)
	Well-Differentiated Thyroid Cancer (WDTC)	166 (0.9 %)	166 (1.0 %)	8 (0.6 %)	1 (0.1 %)
Skin	Melanoma (MEL)	729 (3.9 %)	619 (3.8 %)	187 (14.0 %)	43 (4.4 %)
Breast	Invasive Breast Carcinoma (BRCA)	2,558 (13.6 %)	3,113 (19.1 %)	274 (20.5 %)	85 (8.8 %)
Gynecologic	Ovarian Epithelial Tumor (OVT)	1,213 (6.4 %)	525 (3.2 %)	81 (6.1 %)	58 (6.0 %)
Gynecologic	Endometrial Carcinoma (UCEC)	703 (3.7 %)	703 (4.3 %)	34 (2.5 %)	18 (1.9 %)
Hamatalani	Acute Myeloid Leukemia (AML)	150 (0.8 %)	1 (0.0 %)	0 (0.0 %)	1 (0.1 %)
Hematologic	Non-Hodgkin Lymphoma (NHL)	110 (0.6 %)	88 (0.5 %)	0 (0.0 %)	1 (0.1 %)
	Prostate Adenocarcinoma (PRAD)	601 (3.2 %)	1,222 (7.5 %)	27 (2.0 %)	27 (2.8 %)
Genitourinary	Renal Cell Carcinoma (RCC)	457 (2.4 %)	497 (3.1 %)	39 (2.9 %)	24 (2.5 %)
	Bladder Urothelial Carcinoma (BLCA)	550 (2.9 %)	505 (3.1 %)	41 (3.1 %)	21 (2.2 %)
	Diffuse Glioma (DIFG)	2,041 (10.8 %)	1,069 (6.6 %)	47 (3.5 %)	25 (2.6 %)
Neuro					




Figure 2






Figure 3




Figure 3





Figure 4


Table 2	Tal	ble	е 2	2
---------	-----	-----	-----	---


	Concordant treatment group	Discordant treatment group				
	(n = 77)	(n = 81)				
Sex; male-female ratio	0.442-0.558	0.556-0.444				
Age at sequencing $(95\% \text{ C.I.})$	64 (61.6 - 66.4)	62(59.4 - 64.6)				
Prediction uncertainty (in entropy; 95% C.I.)	$0.550 \ (0.426 - 0.675)$	0.988 (0.850 - 1.127)				
On	coPanel version (proportion in	%)				
v1	1 (1.30%)	1 (1.24%)				
v2	9(11.7%)	15 (18.5%)				
v3	67 (87.0%)	65~(80.2%)				
Mutational burden (95% C.I.)	$0.027 \ (0.021 - 0.033)$	$0.033 \ (0.027 - 0.040)$				
CNA burden (95% C.I.)	$0.201 \ (0.166 - 0.236)$	$0.186\ (0.155 - 0.217)$				
Predicted	primary cancer groups (propor	tion in %)				
Lung	15 (19.5%)	24 (29.6%)				
Breast	5 (6.50%)	11 (13.6%)				
GI	33~(42.9%)	16~(19.8%)				
Gyn	9(11.7%)	5(6.17%)				
Others	15~(19.5%)	25 (31.0%)				
N	Ietastatic sites (proportion in $\%$	б)				
Brain	4 (5.20%)	8 (9.88%)				
Bone	7 (9.10%)	10 (12.3%)				
Soft tissue	6 (7.79%)	5 (6.17%)				
Others	60 (77.9%)	58 (71.6%)				
Histology (proportion in %)						
Adenocarcinoma	41 (53.2%)	32 (39.5%)				
Neuroendocrine	9~(11.7%)	11 (13.6%)				
Squamous cell	2(2.60%)	6 (7.41%)				
Others	25~(32.5%)	32~(39.5%)				
Treatment start date (95% C.I.)	2018-4-30 (2017-12-24 - 2018-9-3)	2018-3-1 (2017-10-28 - 2018-7-3)				



Discordant treatments (n = 81)

First-line treatment at DFCI






Concordant treatments (n = 77) OncoNPC First-line treatment at DFCI cancer types EGC OXALIPLATIN/FLUOROURACIL/LEUCOVORIN FOLFIRINOX PAAD PACHTAXEL/GEMCITABINE COADREAD OLAPARIB _ BEVACIZUMAB/OXALIPLATIN/FLUOROURACIL/LEUCOVORIN PEMETREXED/CARBOPLATIN PEMETREXED PEMBROLIZUMAB/PEMETREXED/CARBOPLATIN PEMETREXED/CISPLATIN NSCLC NIVOLUMAB -PEMBROLIZUMAB CARBOPLATIN/PACLITAXEL CAROOFLATIN/SCHARTIN СНО OVT BLCA GINET OCTREOTIDE BRCA PANET

CAPECITABLE PERTUZUMAB/TRASTUTAB/TRASTUZUMAB/TRASTUZUMAB/TRASTUTAB/TRASTUZUMAB/TRASTUTAB/TRASTUZUMAB/T



-UCEC

PRAD



(e)